We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
Read MoreHide Full Article
ARIAD Pharmaceuticals, Inc. announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on the receipt of accelerated approval in Dec 2012.
Iclusig is approved for the treatment of adult patients suffering from T315I-positive chronic myeloid leukemia (CML: chronic, accelerated or blast phase) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) or for whom no other TKI therapy is approved.
Over the last one month, ARIAD’s share price has surged 58.3% compared to the Zacks classified Drugs Market of 7.6%. We expect shares to gain higher following the latest approval.
Note that Iclusig, ARIAD’s only marketed drug, is approved in both the U.S. and the EU. The latest approval and label update was based on long-term safety and efficacy data from the pivotal phase II PACE clinical trial (n=449) on Iclusig in heavily pretreated patients with resistant or intolerant CML or Ph+ ALL. Data from the PACE study showed that a minimum follow-up of 48 months with Iclusig led to sustained long-term cytogenetic and molecular responses in many chronic-phase CML patients.
The four-year follow-up data demonstrated the durability of the high response rates achieved with Iclusig in refractory CML patients for whom no other TKI therapy is appropriate, including those with the T315I mutation.
Notably, Iclusig was granted orphan drug designation by the FDA for the treatment of leukemia.
This September, Iclusig received Japanese approval for the treatment of CML and is being marketed by partner Otsuka.
Apart from the PACE study, ARIAD is conducting two other studies on Iclusig – the OPTIC dose-ranging study and the OPTIC-2L study for second-line chronic-phase CML.
Even though the CML market represents significant potential, Iclusig faces intense competition, as the market is crowded by Novartis AG’ (NVS - Free Report) Gleevec, Bristol-Myers Squibb Company’s (BMY - Free Report) Sprycel and Pfizer Inc.’s (PFE - Free Report) Bosulif among others. All the three drugs are approved for the treatment of CML in patients who are either resistant or intolerant to prior TKI therapies.
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
ARIAD Pharmaceuticals, Inc. announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on the receipt of accelerated approval in Dec 2012.
Iclusig is approved for the treatment of adult patients suffering from T315I-positive chronic myeloid leukemia (CML: chronic, accelerated or blast phase) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) or for whom no other TKI therapy is approved.
Over the last one month, ARIAD’s share price has surged 58.3% compared to the Zacks classified Drugs Market of 7.6%. We expect shares to gain higher following the latest approval.
Note that Iclusig, ARIAD’s only marketed drug, is approved in both the U.S. and the EU. The latest approval and label update was based on long-term safety and efficacy data from the pivotal phase II PACE clinical trial (n=449) on Iclusig in heavily pretreated patients with resistant or intolerant CML or Ph+ ALL. Data from the PACE study showed that a minimum follow-up of 48 months with Iclusig led to sustained long-term cytogenetic and molecular responses in many chronic-phase CML patients.
The four-year follow-up data demonstrated the durability of the high response rates achieved with Iclusig in refractory CML patients for whom no other TKI therapy is appropriate, including those with the T315I mutation.
Notably, Iclusig was granted orphan drug designation by the FDA for the treatment of leukemia.
This September, Iclusig received Japanese approval for the treatment of CML and is being marketed by partner Otsuka.
Apart from the PACE study, ARIAD is conducting two other studies on Iclusig – the OPTIC dose-ranging study and the OPTIC-2L study for second-line chronic-phase CML.
Even though the CML market represents significant potential, Iclusig faces intense competition, as the market is crowded by Novartis AG’ (NVS - Free Report) Gleevec, Bristol-Myers Squibb Company’s (BMY - Free Report) Sprycel and Pfizer Inc.’s (PFE - Free Report) Bosulif among others. All the three drugs are approved for the treatment of CML in patients who are either resistant or intolerant to prior TKI therapies.
ARIAD PHARMA Price
ARIAD PHARMA Price | ARIAD PHARMA Quote
Zacks Rank
ARIAD currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>